Xilio Therapeutics
31 hedge funds and large institutions have $13.7M invested in Xilio Therapeutics in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 6 closing their positions.
122% more capital inflows, than outflows
Capital inflows: $4.23M | Capital outflows: $1.91M
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
3% more funds holding
Funds holding: 30 → 31 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.97% less ownership
Funds ownership: 45.28% → 39.31% (-6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.75M |
| 2 |
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$1.1M |
| 3 |
Morgan Stanley
New York
|
+$996K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$110K |
| 5 |
Renaissance Technologies
New York
|
+$50.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$1.07M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$572K |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$73.9K |
| 4 |
Millennium Management
New York
|
-$64.8K |
| 5 |
PFG Investments
Woodbury,
New York
|
-$32.4K |
XLO Hedge Fund Activity: Q2 2024 in Review
31 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q2 2024, worth a combined $13.7M — up 2% from $13.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new XLO positions and 6 closed out — a net gain of 1 holder — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Rock Springs Capital Management, adding an estimated $1.75M. The largest seller was Atlas Venture Life Science Advisors, exiting entirely with an estimated $1.07M sold.
- 31 institutional investors held Xilio Therapeutics (XLO) as of Q2 2024, up from 30 in Q1 2024.
- Funds reported $13.7M of Xilio Therapeutics stock for Q2 2024, up 2% quarter-over-quarter.
- 7 funds opened new Xilio Therapeutics positions in Q2 2024 and 6 closed out, a net change of +1 holder.
- The largest Xilio Therapeutics buyer in Q2 2024 was Rock Springs Capital Management, an estimated $1.75M added.
- The largest Xilio Therapeutics seller in Q2 2024 was Atlas Venture Life Science Advisors, an estimated $1.07M sold.
Based on aggregated 13F filings for Q2 2024.